A detailed history of Raymond James & Associates transactions in Ocular Therapeutix, Inc stock. As of the latest transaction made, Raymond James & Associates holds 142,108 shares of OCUL stock, worth $1.18 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
142,108
Previous 163,408 13.03%
Holding current value
$1.18 Million
Previous $1.12 Million 10.65%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$6.45 - $9.23 $137,385 - $196,599
-21,300 Reduced 13.03%
142,108 $1.24 Million
Q2 2024

Jul 19, 2024

SELL
$4.2 - $8.69 $132,825 - $274,821
-31,625 Reduced 16.22%
163,408 $1.12 Million
Q1 2024

Apr 22, 2024

BUY
$3.85 - $10.93 $254,180 - $721,609
66,021 Added 51.17%
195,033 $1.77 Million
Q4 2023

Jan 16, 2024

BUY
$2.08 - $4.52 $17,578 - $38,198
8,451 Added 7.01%
129,012 $575,000
Q3 2023

Oct 24, 2023

BUY
$3.14 - $5.04 $230,237 - $369,552
73,324 Added 155.23%
120,561 $378,000
Q2 2023

Jul 25, 2023

SELL
$4.6 - $7.64 $8,372 - $13,904
-1,820 Reduced 3.71%
47,237 $243,000
Q1 2023

Apr 14, 2023

BUY
$2.79 - $6.27 $29,537 - $66,380
10,587 Added 27.52%
49,057 $258,000
Q4 2022

Feb 08, 2023

SELL
$2.61 - $4.41 $49,472 - $83,591
-18,955 Reduced 33.01%
38,470 $108,000
Q3 2022

Oct 25, 2022

BUY
$4.09 - $6.5 $23,509 - $37,362
5,748 Added 11.12%
57,425 $238,000
Q2 2022

Aug 12, 2022

SELL
$3.01 - $5.22 $7,290 - $12,642
-2,422 Reduced 4.48%
51,677 $208,000
Q1 2022

May 11, 2022

BUY
$4.83 - $7.35 $1,188 - $1,808
246 Added 0.46%
54,099 $268,000
Q4 2021

Feb 08, 2022

SELL
$6.16 - $12.07 $245,771 - $481,568
-39,898 Reduced 42.56%
53,853 $375,000
Q3 2021

Nov 02, 2021

BUY
$9.7 - $14.34 $289,234 - $427,590
29,818 Added 46.64%
93,751 $938,000
Q2 2021

Aug 11, 2021

BUY
$13.43 - $19.16 $57,466 - $81,985
4,279 Added 7.17%
63,933 $907,000
Q1 2021

May 14, 2021

BUY
$15.82 - $22.11 $25,470 - $35,597
1,610 Added 2.77%
59,654 $979,000
Q4 2020

Feb 12, 2021

SELL
$7.91 - $22.95 $279,547 - $811,075
-35,341 Reduced 37.84%
58,044 $1.2 Million
Q3 2020

Nov 04, 2020

BUY
$7.36 - $9.87 $21,012 - $28,178
2,855 Added 3.15%
93,385 $711,000
Q2 2020

Jul 28, 2020

BUY
$4.67 - $8.95 $125,412 - $240,352
26,855 Added 42.18%
90,530 $754,000
Q1 2020

Apr 21, 2020

BUY
$3.95 - $7.4 $251,516 - $471,195
63,675 New
63,675 $315,000

Others Institutions Holding OCUL

About OCULAR THERAPEUTIX, INC


  • Ticker OCUL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,966,896
  • Market Cap $641M
  • Description
  • Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cat...
More about OCUL
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.